General
Preferred name
AMINOSALICYLIC ACID
Synonyms
AMINOSALICYLATE SODIUM ()
Acids, aminosalicyli ()
4-aminosalicylic acid ()
SODIUM AMINOSALICYLATE ()
para-aminosalicylic acid ()
Aminopar ()
Sodium 4-Aminosalicylate ()
4-Amino-salicylic acid sodium salt ()
4-aminosalicylate sodium ()
4-aminosalicylic acid, Block ()
Sodium 4-aminosalicylate (dihydrate) ()
4-Aminosalicylic acid (sodium salt dihydrate) ()
para-aminosalicylic acid, Aminosalicylic acid, 4-aminosalicylate ()
p-Aminosalicylic acid sodium salt dihydrate ()
Sodium 4-aminosalicylate dihydrate ()
AMINOSALICYLATE POTASSIUM ()
AMINOSALICYLATE CALCIUM ()
Sodium Aminosalicylate ()
Granupas ()
Paser ()
Parasal ()
Aminosalicylic acid resin complex ()
PAS ()
P-aminosalicylic acid ()
Aminosalicylic acid component of neopasalate ()
Rezipas ()
Aminosalicylate ()
Benzoic acid, 4-amino-2-hydroxy- ()
Granupas (previously para-aminosalicylic acid lucane) ()
NSC-2083 ()
Calcium aminosalicylate ()
Nippas calcium ()
Aminosalicylate calcium trihydate ()
Aminosalicylate calcium anhydrous ()
Anhydrous calcium aminosalicylate ()
P.A.S. Sodium ()
Parasal Sodium ()
Para-aminosodium salicylate ()
Teebacin ()
Sodium P.A.S. ()
Pasalon ()
Aminacyl ()
NSC-755862 ()
Nemasol sodium ()
Paramisan sodium ()
Pas-c ()
Aminosalyle Sodium ()
Aminosalicylate sodium ()
P-aminosalicylic acid potassium salt ()
Potassium aminosalicylate ()
Paskalium ()
4-Aminosalicylic Acid-d7 ()
P&D ID
PD010156
CAS
6018-19-5
133-10-8
8031-28-5
65-49-6
133-09-5
Tags
available
drug candidate
drug
Approved by
FDA
First approval
1950
1955
Drug indication
Ulcerative colitis
Inflammatory bowel disease
Tuberculosis
Pulmonary and extrapulmonary tuberculosis
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION 4-Aminosalicylic acid is an inhibitor for dihydrofolate reductase (DHFR) and an antituberculous agent. 4-Aminosalicylic acid exhibits anti-inflammatory activity and can be used in research of inflammatory bowel disease (IBD). 4-Aminosalicylic acid is orally active[1][1][3].
PRICE 29
DESCRIPTION Sodium 4-aminosalicylate dihydrate (4-Aminosalicylic acid sodium salt dihydrate) is an inhibitor for dihydrofolate reductase (DHFR) and an antituberculous agent. Sodium 4-aminosalicylate dihydrate exhibits anti-inflammatory activity and can be used in research of inflammatory bowel disease (IBD). Sodium 4-aminosalicylate dihydrate is orally active[1][1][3].
PRICE 29
DESCRIPTION Aminosalicylic acid is an aminosalicylate drug used to induce remission in ulcerative colitis. Aminosalicylic acid is an anti-mycobacterial agent used with other anti-tuberculosis drugs for the treatment of all forms of active tuberculosis due to susceptible strains of tubercle bacilli. (Enamine Bioactive Compounds)
DESCRIPTION 4-Aminosalicylic acid (para-aminosalicylic acid) is an analog of para-aminobenzoic acid (PABA) with antitubercular activity. (TargetMol Bioactive Compound Library)
DESCRIPTION p-Aminosalicylic acid sodium salt dihydrate is one of the antimycobacterial drugs currently used for multidrug-resistant tuberculosis.It is an antibiotic used to treat tuberculosis via NF-κB inhibition and free radical scavenging. (BOC Sciences Bioactive Compounds)
DESCRIPTION Sodium 4-aminosalicylate dihydrate (4-Amino-salicylic acid sodium salt) is the sodium salt form of aminosalicylic acid, an analog of para-aminobenzoic acid (PABA) with antitubercular activity. Sodium 4-aminosalicylate dihydrate exerts its bacteriostatic activity against Mycobacterium tuberculosis by competing with PABA for enzymes involved in folate synthesis, thereby suppressing growth and reproduction of M. tuberculosis, eventually leading to cell death. (TargetMol Bioactive Compound Library)
Compound Sets
28
AdooQ Bioactive Compound Library
A17558
BOC Sciences Bioactive Compounds
p-aminosalicylic-acid-sodium-salt-dihydrate-cas-6018-19-5-item-84-72763
Cayman Chemical Bioactives
33449
43800
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1169
CHEMBL2096646
CHEMBL1200584
ChEMBL Drugs
CHEMBL1169
CHEMBL2096646
CHEMBL2105983
CHEMBL1200584
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00233
DrugBank Approved Drugs
DB00233
DrugCentral
2050
DrugCentral Approved Drugs
2050
DrugMAP
DM4Z1CH
DMENSL5
DrugMAP Approved Drugs
DMENSL5
DrugMatrix
Enamine Bioactive Compounds
EBC-03237
Enamine BioReference Compounds
Guide to Pharmacology
13652
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1200966
MedChem Express Bioactive Compound Library
HY-I0447
HY-I0447A
NCATS Inxight Approved Drugs
5B2658E0N2
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
aminosalicylate-sodium
4-aminosalicylic-acid
TargetMol Bioactive Compound Library
T1296
T0020
The Spectrum Collection
External IDs
110
Properties
(calculated by RDKit )
Molecular Weight
153.04
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
1
Ring Count
1
Aromatic Ring Count
1
cLogP
0.67
TPSA
83.55
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.52
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
Unknown molecular target
cyclooxygenase inhibitor
Target
cyclooxygenase
ALOX5
antibiotic
Bacterial
COX-2
MPO
NF-κB
Free radical scavengers
ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2
NF-¦ÊB
Indication
inflammatory bowel disease, ulcerative colitis
Pathway
Immunology/Inflammation
Metabolism
Microbiology/virology
Neuroscience
oxidation-reduction
Anti-infection
Source data